Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ATNM, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Allogeneic Hematopoietic Stem Cell Transplant… | Acute Leukemia | Phase 2/3 · NCT07157514 | Not yet recruiting |
| Iodine I 131 Apamistamab | Acute Myeloid Leukemia | Phase 3 · NCT02665065 | Active not recruiting |
| Conventional Care | Acute Myeloid Leukemia | Phase 3 · NCT02665065 | Active not recruiting |
| 131I-apamistamab | Acute Leukemia | Phase 2/3 · NCT07157514 | Not yet recruiting |
| Fludarabine | Acute Leukemia | Phase 2/3 · NCT07157514 | Not yet recruiting |
| Lintuzumab-Ac225 | Acute Myeloid Leukemia | Phase 1/2 · NCT03867682 | Unknown |
| Chimeric Antigen Receptor T-cells | Non Hodgkin Lymphoma | Phase 1/2 · NCT06768905 | Recruiting |
| Lintuzumab AC 225 | Refractory Multiple Myeloma | Phase 1 · NCT02998047 | Terminated |
| Actinium Ac 225 Lintuzumab | Leukemia | Phase 1 · NCT00672165 | Completed |
| 131I-apamistmab | Sickling Disorder Due to Hemoglobin S | Phase 1 · NCT07015684 | Recruiting |
Also used in these trials (approved or third-party drugs, not ATNM's own candidates): Cyclophosphamide, Cytarabine, Venetoclax, Spironolactone, Furosemide, Azacitidine, Alemtuzumab, Sirolimus.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ATNM holds $36.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $5.5M/quarter from operations, an estimated runway of 19.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 8 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ATNM files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Sandesh Seth Chief Executive Officer, Director · +1.13M options |
Insider | 1,965,355 | 6.25% | 2026-09-02 |
| Matthew T David Chief Financial Officer · +250,000 options |
Insider | 250,000 | 0.80% | 2026-10-14 |
| Adeela Kamal Chief Scientific Officer |
Insider | 213,648 | 0.68% | 2026-09-03 |
| Steffen Wilhem Heeger Chief Medical Officer |
Insider | 153,868 | 0.49% | 2026-09-03 |
| C. David Nicholson, Director · +94,200 options |
Insider | 63,300 | 0.20% | 2026-09-02 |
| Richard I Steinhart Director · +94,200 options |
Insider | 63,116 | 0.20% | 2026-09-02 |
| Ajit Shetty Director · +92,400 options |
Insider | 62,357 | 0.20% | 2026-09-02 |
| Jeffrey W. Chell Director · +92,400 options |
Insider | 61,600 | 0.20% | 2026-09-02 |
| June Sherie Almenoff Director · +27,000 options |
Insider | 18,000 | 0.06% | 2026-09-02 |
Share count 31,441,436 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATNM and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →